Citius Pharmaceuticals (NASDAQ:CTXR) Issues Earnings Results

Citius Pharmaceuticals (NASDAQ:CTXR) issued its quarterly earnings results on Friday. The company reported ($0.38) EPS for the quarter, FiscalAI reports. The company had revenue of $3.94 million for the quarter.

Citius Pharmaceuticals Price Performance

CTXR stock opened at $0.77 on Friday. The business has a 50 day simple moving average of $0.89 and a 200-day simple moving average of $1.16. The firm has a market capitalization of $15.89 million, a PE ratio of -0.23 and a beta of 1.61. Citius Pharmaceuticals has a 1 year low of $0.63 and a 1 year high of $2.97.

Analysts Set New Price Targets

CTXR has been the topic of a number of research reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Citius Pharmaceuticals in a research note on Monday, December 29th. Wall Street Zen upgraded Citius Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Saturday, December 27th. Finally, D. Boral Capital reaffirmed a “buy” rating and issued a $6.00 price target on shares of Citius Pharmaceuticals in a research note on Thursday, December 4th. One analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $6.00.

Hedge Funds Weigh In On Citius Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Asset Advisory Group Inc. acquired a new stake in shares of Citius Pharmaceuticals in the 4th quarter worth $46,000. NewEdge Advisors LLC purchased a new stake in shares of Citius Pharmaceuticals in the second quarter valued at about $40,000. XTX Topco Ltd acquired a new stake in Citius Pharmaceuticals during the second quarter worth about $32,000. Finally, Arkadios Wealth Advisors raised its stake in Citius Pharmaceuticals by 100.0% during the second quarter. Arkadios Wealth Advisors now owns 20,000 shares of the company’s stock worth $32,000 after purchasing an additional 10,000 shares during the period. Institutional investors and hedge funds own 16.88% of the company’s stock.

About Citius Pharmaceuticals

Citius Pharmaceuticals is a clinical?stage specialty pharmaceutical company focused on the development and commercialization of critical care products and novel drug delivery systems. Headquartered in Cranford, New Jersey, the company aims to address unmet medical needs in acute care, hospital?acquired infections and subcutaneous delivery of biologics. Citius operates as a Delaware corporation and trades on the NASDAQ under the symbol CTXR.

One of the company’s leading assets is Mino-Lok, an antibiotic lock solution designed to treat catheter?related bloodstream infections without catheter removal.